Centre Eugène Marquis - Academic Profile

Publications

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu , Richard S. Finn , Julien Edeline +56 more

2018 The Lancet Oncology 2448 citations

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi , Cristina Saura , Toshinari Yamashita +22 more

Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...

2019 New England Journal of Medicine 1788 citations

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

2019 The Lancet Oncology 1593 citations

Affiliated Researchers

Institution Info

Type: facility
Country: FR
Publications: 4
Citations: 7,566

External Links

Identifiers

ROR: https://ror.org/01yezas83